Cargando…
Comparative analysis of clinical and immunological profiles across Omicron BA.5.2 subvariants using next-generation sequencing in a Chinese cohort
OBJECTIVE: The Omicron BA.5.2 variant of SARS-CoV-2 has undergone several evolutionary adaptations, leading to multiple subvariants. Rapid and accurate characterization of these subvariants is essential for effective treatment, particularly in critically ill patients. This study leverages Next-Gener...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642935/ https://www.ncbi.nlm.nih.gov/pubmed/37965255 http://dx.doi.org/10.3389/fcimb.2023.1288914 |
_version_ | 1785147048671051776 |
---|---|
author | Huang, Jianliang Xia, Mingkai Liu, Rangjiao Wang, Shaobo Duan, Xinyi Peng, Jiong Li, Enping Zhou, Yanping Li, Chengyou Zhang, Quan Tian, Jixian Wang, Xinjian Su, Zhongrui Tan, Jun Peng, Bo Zhang, Jianhui Li, Jin Dai, Lizhong Lei, Mingsheng |
author_facet | Huang, Jianliang Xia, Mingkai Liu, Rangjiao Wang, Shaobo Duan, Xinyi Peng, Jiong Li, Enping Zhou, Yanping Li, Chengyou Zhang, Quan Tian, Jixian Wang, Xinjian Su, Zhongrui Tan, Jun Peng, Bo Zhang, Jianhui Li, Jin Dai, Lizhong Lei, Mingsheng |
author_sort | Huang, Jianliang |
collection | PubMed |
description | OBJECTIVE: The Omicron BA.5.2 variant of SARS-CoV-2 has undergone several evolutionary adaptations, leading to multiple subvariants. Rapid and accurate characterization of these subvariants is essential for effective treatment, particularly in critically ill patients. This study leverages Next-Generation Sequencing (NGS) to elucidate the clinical and immunological features across different Omicron BA.5.2 subvariants. METHODS: We enrolled 28 patients infected with the Omicron variant, hospitalized in Zhangjiajie People’s Hospital, Hunan, China, between January 20, 2023, and March 31, 2023. Throat swabs were collected upon admission for NGS-based identification of Omicron subvariants. Clinical data, including qSOFA scores and key laboratory tests, were collated. A detailed analysis of lymphocyte subsets was conducted to ascertain the extent of immune cell damage and disease severity. RESULTS: Patients were infected with various Omicron subvariants, including BA.5.2.48, BA.5.2.49, BA.5.2.6, BF.7.14, DY.1, DY.2, DY.3, and DY.4. Despite having 43 identical mutation sites, each subvariant exhibited unique marker mutations. Critically ill patients demonstrated significant depletion in total lymphocyte count, T cells, CD4, CD8, B cells, and NK cells (P < 0.05). However, there were no significant differences in clinical and immunological markers across the subvariants. CONCLUSION: This study reveals that critically ill patients infected with different Omicron BA.5.2 subvariants experience similar levels of cellular immune dysfunction and inflammatory response. Four mutations - ORF1a:K3353R, ORF1a:L3667F, ORF1b:S997P, S:T883I showed correlation with immunological responses although this conclusion suffers from the small sample size. Our findings underscore the utility of NGS in the comprehensive assessment of infectious diseases, contributing to more effective clinical decision-making. |
format | Online Article Text |
id | pubmed-10642935 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106429352023-11-14 Comparative analysis of clinical and immunological profiles across Omicron BA.5.2 subvariants using next-generation sequencing in a Chinese cohort Huang, Jianliang Xia, Mingkai Liu, Rangjiao Wang, Shaobo Duan, Xinyi Peng, Jiong Li, Enping Zhou, Yanping Li, Chengyou Zhang, Quan Tian, Jixian Wang, Xinjian Su, Zhongrui Tan, Jun Peng, Bo Zhang, Jianhui Li, Jin Dai, Lizhong Lei, Mingsheng Front Cell Infect Microbiol Cellular and Infection Microbiology OBJECTIVE: The Omicron BA.5.2 variant of SARS-CoV-2 has undergone several evolutionary adaptations, leading to multiple subvariants. Rapid and accurate characterization of these subvariants is essential for effective treatment, particularly in critically ill patients. This study leverages Next-Generation Sequencing (NGS) to elucidate the clinical and immunological features across different Omicron BA.5.2 subvariants. METHODS: We enrolled 28 patients infected with the Omicron variant, hospitalized in Zhangjiajie People’s Hospital, Hunan, China, between January 20, 2023, and March 31, 2023. Throat swabs were collected upon admission for NGS-based identification of Omicron subvariants. Clinical data, including qSOFA scores and key laboratory tests, were collated. A detailed analysis of lymphocyte subsets was conducted to ascertain the extent of immune cell damage and disease severity. RESULTS: Patients were infected with various Omicron subvariants, including BA.5.2.48, BA.5.2.49, BA.5.2.6, BF.7.14, DY.1, DY.2, DY.3, and DY.4. Despite having 43 identical mutation sites, each subvariant exhibited unique marker mutations. Critically ill patients demonstrated significant depletion in total lymphocyte count, T cells, CD4, CD8, B cells, and NK cells (P < 0.05). However, there were no significant differences in clinical and immunological markers across the subvariants. CONCLUSION: This study reveals that critically ill patients infected with different Omicron BA.5.2 subvariants experience similar levels of cellular immune dysfunction and inflammatory response. Four mutations - ORF1a:K3353R, ORF1a:L3667F, ORF1b:S997P, S:T883I showed correlation with immunological responses although this conclusion suffers from the small sample size. Our findings underscore the utility of NGS in the comprehensive assessment of infectious diseases, contributing to more effective clinical decision-making. Frontiers Media S.A. 2023-10-30 /pmc/articles/PMC10642935/ /pubmed/37965255 http://dx.doi.org/10.3389/fcimb.2023.1288914 Text en Copyright © 2023 Huang, Xia, Liu, Wang, Duan, Peng, Li, Zhou, Li, Zhang, Tian, Wang, Su, Tan, Peng, Zhang, Li, Dai and Lei https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Huang, Jianliang Xia, Mingkai Liu, Rangjiao Wang, Shaobo Duan, Xinyi Peng, Jiong Li, Enping Zhou, Yanping Li, Chengyou Zhang, Quan Tian, Jixian Wang, Xinjian Su, Zhongrui Tan, Jun Peng, Bo Zhang, Jianhui Li, Jin Dai, Lizhong Lei, Mingsheng Comparative analysis of clinical and immunological profiles across Omicron BA.5.2 subvariants using next-generation sequencing in a Chinese cohort |
title | Comparative analysis of clinical and immunological profiles across Omicron BA.5.2 subvariants using next-generation sequencing in a Chinese cohort |
title_full | Comparative analysis of clinical and immunological profiles across Omicron BA.5.2 subvariants using next-generation sequencing in a Chinese cohort |
title_fullStr | Comparative analysis of clinical and immunological profiles across Omicron BA.5.2 subvariants using next-generation sequencing in a Chinese cohort |
title_full_unstemmed | Comparative analysis of clinical and immunological profiles across Omicron BA.5.2 subvariants using next-generation sequencing in a Chinese cohort |
title_short | Comparative analysis of clinical and immunological profiles across Omicron BA.5.2 subvariants using next-generation sequencing in a Chinese cohort |
title_sort | comparative analysis of clinical and immunological profiles across omicron ba.5.2 subvariants using next-generation sequencing in a chinese cohort |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642935/ https://www.ncbi.nlm.nih.gov/pubmed/37965255 http://dx.doi.org/10.3389/fcimb.2023.1288914 |
work_keys_str_mv | AT huangjianliang comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort AT xiamingkai comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort AT liurangjiao comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort AT wangshaobo comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort AT duanxinyi comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort AT pengjiong comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort AT lienping comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort AT zhouyanping comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort AT lichengyou comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort AT zhangquan comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort AT tianjixian comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort AT wangxinjian comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort AT suzhongrui comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort AT tanjun comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort AT pengbo comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort AT zhangjianhui comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort AT lijin comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort AT dailizhong comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort AT leimingsheng comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort |